The 6 target miRNAs contribute to the molecular mechanisms of sorafenib resistance in HCC cells by commonly dysregulating PTEN, and sequentially resulting in the activation of AKT (Figure 7). The gene discussed is AKT1; the disease is hepatocellular carcinoma.